Tag: the war on (some) drugs

USDA Releases New Hemp Handbook As Agency Works To Rebuild A Post-Prohibition Seed Bank

As the U.S. Department of Agriculture (USDA) works to rebuild a government seed bank for hemp that was destroyed during prohibition, the agency is issuing updated guidance on how to identify, describe and evaluate different varieties of the plant.

USDA’s latest version of its Hemp Descriptor and Phenotyping Handbook, released earlier this summer, is the agency’s deepest dive yet into the different forms and qualities of hemp. Intended to help researchers better differentiate between hemp varieties, the new document includes all sorts of details on the morphology, yield, cannabinoid content, oil production, seed viability, fiber quality, pathogen resistance and various other traits.

The eventual goal is to allow users of the genetic repository, including hemp scientists and breeders, to more fully understand the range of hemp varieties and and select them for various applications.

As USDA puts it, “Robust, reliable and high-dimensional data generated from these phenotyping efforts will empower conservation of hemp genetic diversity and aid selection of materials with unique trait combinations for breeding programs.”

Keep reading

Rescheduling Won’t End The War On Cannabis, But Could Open A New Battlefront If We’re Not Careful

Contrary to decades of reefer madness propagated by our federal government, the Food and Drug Administration (FDA) now admits that marijuana does have accepted medical use. However, reports of the death of cannabis prohibition are exaggerated. No doubt, the conclusion of FDA’s scientific review of marijuana’s current Schedule I status is a welcome milestone in federal cannabis policy.

But while the Department of Health and Human Services’s (HHS) August 29, 2023 recommendation to the Drug Enforcement Administration (DEA) to reschedule marijuana based on FDA’s review will finally bring relief from the federal gross receipts tax levied on struggling state-licensed cannabis businesses, it also underscores the urgent need to both (1) continue pressing forward on descheduling efforts before critical momentum evaporates and certain industry stakeholders effectively settle for rescheduling without full decriminalization, and (2) demand that marijuana be exempted from existing categories of FDA-regulated products to preserve state medical and adult use cannabis markets.

Before proceeding, it’s important to remember that rescheduling would not apply the federal Food Drug and Cosmetic Act (FDCA) to marijuana for the first time—it applies right now, and like the federal Controlled Substances Act (CSA), would continue to apply after rescheduling. But absent any statutory authority permitting FDA to do otherwise, the FDCA would continue to apply after descheduling too, just as it does to hemp products. I previously noted this in “Cannabis Cannibalism: How Federal Rescheduling Could Consume the State-Licensed Industry Without Safe Harbors Under the Federal Food, Drug and Cosmetic Act,” available here.

However, moving marijuana from Schedule I to Schedule III will shift enforcement priorities (and the incentives to vigorously pursue these priorities) at both DEA and FDA. Indeed this has been the experience after the CSA’s prohibitions on hemp were relaxed beginning with the 2014 Farm Bill, and then scrapped under the 2018 Farm Bill which descheduled hemp by carving it out of the federal CSA’s definitions of “marijuana” and “THC.” Soon after, purveyors of hemp CBD products began receiving FDA cease-and-desist letters citing prohibited product claims and numerous grounds under the FDCA for prohibiting the interstate commerce in such cannabis products.

Keep reading

Marijuana Is the Sixth Biggest Cash Crop In The US

According to the Leafly Cannabis Harvest Report 2022, marijuana was the sixth most valuable wholesale crop in the United States last year at a $5 billion worth, trailing only corn, soybeans, hay, wheat and cotton.

The calculation includes only crops in states where state-sanctioned sales of legal weed are already up and running and exclude production in medical marijuana-only states.

Statista’s Katharina Buchholz reports that 2022 saw a cannabis harvest of 2,834 metric tons, up 24 percent from 2021.

Keep reading

GOP Congressman’s Bill Would Cut Federal Funding For States And Tribes That Legalize Marijuana

Legislation introduced on Friday by a North Carolina congressman seeks to slash a portion of federal funding to individual U.S. states as well as Native tribes that legalize marijuana.

The so-called Stop Pot Act, sponsored by U.S. Rep. Chuck Edwards (R-NC), would withhold 10 percent of federal highway funding to jurisdictions “in which the purchase or public possession of marijuana for recreational purposes is lawful.” Introduction of the bill comes less than a week before a tribe in Edwards’s home state votes on an adult-use marijuana legalization referendum.

Edwards argues that state and tribal laws allowing cannabis use by adults are an affront to U.S. law.

“The laws of any government should not infringe on the overall laws of our nation, and federal funds should not be awarded to jurisdictions that willfully ignore federal law,” he said in a press release. “During a time when our communities are seeing unprecedented crime, drug addiction, and mental illness, the Stop Pot Act will help prevent even greater access to drugs and ease the strain placed on our local law enforcement and mental health professionals who are already stretched thin.”

Keep reading

Marijuana Should Be De‐​Scheduled, Not Re‐​Scheduled

Bloomberg News is reporting that U.S. Department of Health and Human Services Assistant Secretary for Health Rachel Levine has sent a letter to Drug Enforcement Administrator Anne Milgram asking her agency to reclassify marijuana (cannabis) as a Schedule III drug. The DEA defines Schedule III drugs as “drugs with a moderate to low potential for physical and psychological dependence.” The agency currently classifies marijuana as Schedule I: a drug “with no currently accepted medical use and a high potential for abuse.” Of course, that definition begs the question, “Currently accepted by whom?” But an even more important question is, “Why should a plant people have been growing and using recreationally for millennia be scheduled as a drug when alcohol is not?”

When Congress authorized the law enforcement agency to judge the clinical applications, efficacy, and potential dangers of drugs, it authorized cops to practice medicine. And they have been engaging in malpractice. For example, no serious person would argue that marijuana has “no currently accepted medical use.” As far back as 1916, Sir William Osler, the so‐​called “father of modern medicine,” recommended cannabis as the “drug of choice” for treating migraines. But cannabis’s history of “accepted medical use” dates back to at least 2800 B.C.

The DEA also schedules diamorphine (brand‐​named “heroin” by Bayer, its manufacturer in the 19th century) Schedule I even though it is legally used in the U.K. and much of the developed world to treat pain and is employed for medication‐​assisted treatment of opioid use disorder (OUD) in Switzerland, the Netherlands, Germany, Canada, the U.K, Denmark, and Spain.

And even though a bipartisan consensus is emerging that psychedelics may be extremely helpful in treating post‐​traumatic stress disorder, depression, addiction, and compulsive disorders, and in end‐​of‐​life care, the DEA placed them on Schedule I, depriving researchers, clinicians, and patients of these tools for 50 years.

Keep reading

HOW CALIFORNIA COPS EXPLOIT LEGAL GRAY AREAS TO CONTINUE THEIR WAR ON CANNABIS

Zeke Flatten was driving southbound on Highway 101 in Northern California in December 2017 when he was pulled over by an unmarked SUV with flashing emergency lights.

Two officers clad in green, military-style garb and bulletproof vests approached Flatten’s vehicle but didn’t identify themselves. After asking Flatten if he knew how fast he was going, one of the men told him they suspected he was transporting cannabis, according to court documents. Flatten was immediately suspicious.

“He never mentioned anything else about the reason, probable cause, why he stopped me,” Flatten said in an interview with The Appeal.

The officers were correct, however: Flatten, a film producer and former undercover cop who’d temporarily relocated to Northern California, had three pounds of marijuana, including a few rolled joints, in the car—worth over $3,000 at the time. Flatten says he was working on a number of cannabis-related projects and was driving to a lab to test the weed, which he’d hoped to sell legally.

Just over a year before the stop, California had voted to legalize the personal cultivation and possession of up to an ounce of marijuana with the passage of Proposition 64. Under the measure, possession of larger amounts of cannabis was reduced from a felony offense to a misdemeanor, punishable by up to six months of incarceration and a maximum $500 fine.

But marijuana remains illegal at the federal level, classified as a Schedule 1 substance alongside drugs like heroin, LSD, and MDMA, known as Ecstasy. When the officers identified themselves as members of the Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), a federal agency, Flatten said he started to realize something was off.

“There’s no patches, there’s no badges, there’s no name tags,” Flatten said.

Flatten says he offered to show the officers his medical marijuana card, which should have allowed him to have the cannabis. But they didn’t want to look at the card. He figured if the agents believed the marijuana was illegal, they’d take it and provide him a receipt for the seizure, which would give him a chance to argue his case in court, Flatten said.

Instead, they proceeded to confiscate the cannabis from the back of Flatten’s car without running his name for warrants, or issuing a traffic ticket, court summons, or even documentation of the seizure, Flatten said. The officers did tell him that he might be getting a letter from the federal government. But he never did.

Keep reading

Tucker Carlson claims Barack Obama enjoyed smoking CRACK and having gay sex – but that nobody reported it ahead of 2008 election

Tucker Carlson has claimed Barack Obama was smoking crack and having sex with men – but the media failed to report it ahead of the 2008 presidential election.

The former Fox News host repeated the accusation of Larry Sinclair who alleged that Obama bought and smoked cocaine before they had sex in 1999. 

The allegation, which emerged while then-Senator Obama was gearing up for the presidential election, was roundly condemned as an attempted political hatchet-job.

But Carlson claimed Wednesday that it was ‘really clear’ that Obama had been having a gay affair. He claimed the media didn’t run the story because the Obama campaign team threatened to refuse access to the Democratic candidate.

Carlson, 54, speaking on the popular Adam Carolla Show, said: ‘In 2008, it became really clear that Barack Obama had been having sex with men and smoking crack.’

DailyMail.com has contacted Obama’s representatives for comment. 

Keep reading

Psilocybin Associated With ‘Significantly’ Reduced Symptoms Of Major Depression After One Dose, American Medical Association Study Finds

People with major depression experienced “clinically significant sustained reduction” in their symptoms after just one dose of psilocybin, a new study published by the American Medical Association (AMA) found.

A team of 18 researchers from institutions including Yale University, Johns Hopkins University, NYU Langone Center for Psychedelic Medicine and San Francisco Veterans Affairs Medical Center investigated the association, carrying out a randomized clinical trial involving 104 adults with major depressive disorder (MDD).

For the study, published in the Journal of the American Medical Association (JAMA) on Thursday, people with major depressive disorder were administered 25mg of synthetic psilocybin at 11 different clinics across the U.S. and monitored for changes in symptoms over the course of six weeks.

Within eight days, patients who received the psychedelic-assisted treatment, which was also accompanied by psychotherapy sessions, reported reduced depressive symptoms that “maintained across the 6-week follow-up period, without attenuation of the effect.”

Keep reading

Missouri Judge Denies Effort To Stop Recall of 62,000 Marijuana Products

A Missouri judge denied on Wednesday a marijuana company’s effort to stop the recall of 62,000 products containing the company’s THC concentrate that the state deemed a “potential threat to health and safety.”

The company, Delta Extraction, is a Robertsville-based licensed marijuana manufacturer that specializes in making THC distillate, a highly potent and pure form of THC used for things like vape pens, infused pre-rolled joints and edibles.

On August 2, the state regulating agency suspended Delta Extraction’s license after accusing the company of sourcing untested “marijuana or converted hemp from outside of a Missouri licensed cultivation facility.”

The state issued an administrative hold on the products days after and then a full product recall on August 14.

Delta Extraction argued in its August 16 motion for a temporary restraining order that the state’s actions were an “unlawful campaign to destroy Delta’s business through arbitrary, unjustified, and unexplained administrative actions targeting Delta’s products.”

Cole County Circuit Judge Cotton Walker ruled Wednesday that the company did not have grounds to challenge the recall because it has not exhausted the administrative appeal process.

The day after the state suspended their license, Delta filed an appeal with the Administrative Hearing Commission. That decision is still pending.

Keep reading

Top Federal Health Official Confirms At Exactly 4:20 That His Department Is Recommending Marijuana Rescheduling

The head of the top U.S. health agency is confirming news that his department is recommending marijuana rescheduling—posting about the development at exactly 4:20pm ET in an apparent wink to cannabis culture.

Amid a flurry of reactions to reports that the U.S. Department of Health and Human Services (HHS) is advising the Drug Enforcement Administration (DEA) to move cannabis from Schedule I to Schedule III, Secretary Xavier Becerra shared a post about it at the symbolic time on X (the social media site formerly known as Twitter).

If anyone thinks the timing is a coincidence, they probably haven’t been closely following Becerra’s account, as the Biden cabinet official has made a habit of talking about marijuana policy on social media at 4:20 on the dot.

On the day that President Joe Biden announced the scheduling review, for example, the secretary posted about his commitment to following through on the directive—at 4:20.

Keep reading